A new review of current published research into the use of Ivabradine in PoTS (Postural Orthostatic Tachycardia Syndrome) has been published in the Journal of Cardiovascular Pharmacology.
Journal of Cardiovascular Pharmacology
Summary
- There were 11 studies included in the analysis with 305 participants between 2008 to 2020.
- All studies suggested a reduction in heart rate with ivabradine treatment; the proportion of patients with symptomatic benefit ranged from 67% to 100%.
- Overall, there is some evidence that ivabradine is effective in improving POTS symptoms, but larger randomised trials are needed to confirm this.
Extracts
In conclusion, there is low-quality evidence derived from small observational studies and one small randomized trial that ivabradine is effective in reducing heart rate and improving symptoms in patients with POTS. The exact role of ivabradine in treatment of POTS needs to be clarified in further randomized trials and more robust evidence.
MEA Comment
Ivabradine is one of a number of drug treatment options for PoTS (postural orthostatic tachycardia syndrome)
This is a new review of current published research into the use of this drug in PoTS.
The overall conclusion is quoted above
Background information on PoTS and ME/CFS
- The MEA is currently funding Professor Manoj Sivan to assess the use of various approaches to the management of PoTS and other dysautonomia symptoms.
- The MEA has an information booklet that covers the diagnosis and management of PoTS in relation to ME/CFS.
Dr Charles Shepherd,
Trustee and Hon. Medical Adviser to the ME Association,
Member of the 2018-2021 NICE guideline on ME/CFS committee,
Member of the 2002 Chief Medical Officer's Working Group on ME/CFS
